We are monitoring the impact of COVID-19 on Latin America Gastroparesis Drugs Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 5077
Share on
Share on

Latin America Gastroparesis Drugs Market Research Report – Segmented By Drug Class, Disease Type, End User and Country (Brazil, Argentina, Chile, Mexico and Rest of Latin America) – Industry Size, Share, Trends and Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 5077
Pages: 145

The size of the Latin America Gastroparesis Drugs market was around USD 663.39 million in 2021. It is expected to grow at a CAGR of 5.3% to reach USD 858.84 million by 2026. It captures 12% of the global market.

The Latin American market is driven by an increase in the number of procedures resulting in postsurgical gastroparesis, an increase in the geriatric population, and novel medications to treat symptoms, including nausea and vomiting. However, during the forecast period, a surge in demand for user-friendly medicine development, increased healthcare infrastructure, and innovative marketing initiatives by leading vendors in this nation are expected to present the profitable potential for market expansion.

Diabetes is becoming more prevalent due to increased urbanization, sedentary lifestyles, and an increase in the number of people who drink and smoke regularly. Diabetes Mellitus is a prevalent cause of gastroparesis; thus, there is a high need for diagnosis and treatment. Diabetes is also a common cause of gastroparesis, so the gastroparesis medicine market is rising.

Gastroparesis medications also help improve gastrointestinal motility by increasing the frequency of contractions. As a result, they're widely used to treat idiopathic gastroparesis, a condition characterized by severe vomiting, nausea, and upper abdominal pain. This, along with a significant increase in the number of people acquiring gastroparesis due to surgical operations that damage the nervous system and its branches, is fueling market expansion. Furthermore, market revenue growth is expected to be boosted by people's capacity to stretch their budgets and obtain access to medicines over the forecast period.

However, the market's growth is hampered by adverse effects of gastroparesis medications, a complex regulatory process for drug approval, and challenges in gastroparesis diagnosis.

This research report on the Latin American Gastroparesis Drugs market has been segmented and sub-segmented into the following categories:

By Drug Class:

  • Prokinetic Agents 
  • Antiemetic Agents
  • Botulinum Toxin Injections    

By Disease Class:

  • Diabetic Gastroparesis       
  • Idiopathic Gastroparesis    
  • Post-surgical Gastroparesis              
  • Others      

By End User:

  • Hospitals 
  • Pharmacies            
  • Clinics      
  • E-commerce

By Country:

  • Mexico
  • Brazil
  • Argentina
  • Chile
  • Rest of Latin America

Furthermore, according to the United Nations' World Population Aging Report, nearly 75 million people in Latin America and the Caribbean were aged 60 and up in 2016. As a result, these people are more likely to develop idiopathic or diabetic gastroparesis. As a result, Latin America provides a large customer base for gastroparesis medicine makers. The rising prevalence of gastroparesis in Brazil is one of the main reasons for the market's rapid expansion.

In addition, the gastroparesis market can benefit from the rising biotech and medical device sectors. Chile, Colombia, Peru, and Bolivia are some of the leading countries contributing to the growth of the gastroparesis market. Diabetes affects a large portion of the population in these countries. Furthermore, well-established manufacturing enterprises in the regions will aid market expansion. Additionally, rising healthcare expenditures, an increase in the number of hospitals, and well-established healthcare infrastructure are all contributing to the overall regional market's growth.

Furthermore, the implementation of strategic alliances and collaborations by market players in the region is expected to raise gastroparesis awareness, resulting in the market growth over the forecast period. The FDA has approved the device to treat nausea and vomiting caused by idiopathic and diabetic gastroparesis. In the future years, the increased focus on research into stomach electrical stimulation therapy is expected to encourage new technology advances in the gastroparesis market, allowing market players to offer superior alternatives to existing gastroparesis treatment methods.

KEY MARKET PLAYERS:

Allergan, Plc., Abbott Laboratories (Abbott Arzneimittel GmbH), AstraZeneca Plc. Other players in the market are Cadila Pharmaceuticals Ltd., ETX Pharma, Inc, Evoke Pharma, GlaxoSmithKline Plc., Neurogastrx, Inc., Valeant Pharmaceuticals International, Inc., and Theravance Biopharma are a few of the notable companies operating in the Latin American gastroparesis drugs market.

1. Introduction                                

               1.1 Market Definition                    

               1.2 Study Deliverables                  

               1.3 Base Currency, Base Year and Forecast Periods                          

               1.4 General Study Assumptions                 

2. Research Methodology                                          

               2.1 Introduction                             

               2.2 Research Phases                      

                              2.2.1 Secondary Research           

                              2.2.2 Primary Research 

                              2.2.3 Econometric Modelling      

                              2.2.4 Expert Validation  

               2.3 Analysis Design                        

               2.4 Study Timeline                         

3. Overview                                     

               3.1 Executive Summary                

               3.2 Key Inferences                         

               3.3 Epidemology                            

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

               4.1 Market Drivers                         

               4.2 Market Restraints                   

               4.3 Key Challenges                         

               4.4 Current Opportunities in the Market               

5. Market Segmentation                                            

               5.1 Drug Class                  

                              5.1.1 Introduction           

                              5.1.2 Prokinetic Agents 

                              5.1.3 Antiemetic Agents

                              5.1.4 Botulinum Toxin Injections              

                              5.1.5  Y-o-Y Growth Analysis, By Drug Class          

                              5.1.6  Market Attractiveness Analysis, By Drug Class        

                              5.1.7  Market Share Analysis, By Drug Class         

               5.2 Disease Type                            

                              5.2.1 Introduction           

                              5.2.2 Diabetic Gastroparesis       

                              5.2.3 Idiopathic Gastroparesis    

                              5.2.4 Post-surgical Gastroparesis              

                              5.2.5 Others      

                              5.2.6 Y-o-Y Growth Analysis, By Disease Type      

                              5.2.7 Market Attractiveness Analysis, By Disease Type    

                              5.2.8 Market Share Analysis, By Disease Type     

               5.3 End User                     

                              5.3.1 Introduction           

                              5.3.2 Hospitals  

                              5.3.3 Pharmacies             

                              5.3.4 Clinics       

                              5.3.5 E-commerce          

                              5.3.6 Y-o-Y Growth Analysis, By End User             

                              5.3.7 Market Attractiveness Analysis, By End User            

                              5.3.8 Market Share Analysis, By End User             

6. Geographical Analysis                                            

               6.1 Introduction                             

                              6.1.1 Regional Trends    

                              6.1.2 Impact Analysis     

                              6.1.3 Y-o-Y Growth Analysis        

                                             6.1.3.1 By Geographical Area

                                             6.1.3.2 By Drug Class

                                             6.1.3.3 By Disease Type

                                             6.1.3.4 By End User

                              6.1.4  Market Attractiveness Analysis      

                                             6.1.4.1 By Geographical Area

                                             6.1.4.2 By Drug Class

                                             6.1.4.3 By Disease Type

                                             6.1.4.4 By End User

                              6.1.5  Market Share Analysis       

                                             6.1.5.1 By Geographical Area

                                             6.1.5.2 By Drug Class

                                             6.1.5.3 By Disease Type

                                             6.1.5.4 By End User

               6.2 Brazil                           

               6.3 Mexico                        

               6.4 Rest of Latin America                            

7. Strategic Analysis                                      

               7.1 PESTLE analysis                        

                              7.1.1 Political    

                              7.1.2 Economic 

                              7.1.3 Social        

                              7.1.4 Technological        

                              7.1.5 Legal         

                              7.1.6 Environmental       

               7.2 Porter’s Five analysis                             

                              7.2.1 Bargaining Power of Suppliers         

                              7.2.2 Bargaining Power of Consumers     

                              7.2.3 Threat of New Entrants      

                              7.2.4 Threat of Substitute Products and Services

                              7.2.5 Competitive Rivalry within the Industry      

8. Market Leaders' Analysis                                       

               8.1 Allergan, Plc.                            

                              8.1.1 Overview 

                              8.1.2 Product Analysis   

                              8.1.3 Financial analysis  

                              8.1.4 Recent Developments        

                              8.1.5 SWOT analysis       

                              8.1.6 Analyst View          

               8.2 Abbott Laboratories (Abbott Arzneimittel GmbH)                      

               8.3 AstraZeneca Plc.                      

               8.4 Cadila Pharmaceuticals Ltd.                

               8.5 ETX Pharma, Inc                      

               8.6 Evoke Pharma                          

               8.7 GlaxoSmithKline Plc.                             

               8.8 Neurogastrx, Inc.                    

               8.9 Valeant Pharmaceuticals International, Inc.                 

               8.10 Theravance Biopharma                      

9.Competitive Landscape                                           

               9.1 Market share analysis                           

               9.2 Merger and Acquisition Analysis                       

               9.3 Agreements, collaborations and Joint Ventures                          

               9.4 New Product Launches                         

10.Market Outlook and Investment Opportunities                                          

Appendix                                          

               a) List of Tables                

               b) List of Figures                             

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms product type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Latin America Gastroparesis Drugs Market, By Drug Class, From 2021 to 2026 (USD Billion)
  2. Latin America Prokinetic Agents Market, By Region, From 2021 to 2026 (USD Billion)
  3. Latin America Antiemetic Agents Market, By Region, From 2021 to 2026 (USD Billion)
  4. Latin America Botulinum Toxin Injections Market, By Region, From 2021 to 2026 (USD Billion)
  5. Latin America Gastroparesis Drugs Market, By Disease Type, From 2021 to 2026 (USD Billion)
  6. Latin America Diabetic Gastroparesis Market, By Region, From 2021 to 2026 (USD Billion)
  7. Latin America Idiopathic Gastroparesis Market, By Region, From 2021 to 2026 (USD Billion)
  8. Latin America Post-surgical Gastroparesis Market, By Region, From 2021 to 2026 (USD Billion)
  9. Latin America Others Market, By Region, From 2021 to 2026 (USD Billion)
  10. Latin America Gastroparesis Drugs Market, By End User, From 2021 to 2026 (USD Billion)
  11. Latin America Hospitals Market, By Region, From 2021 to 2026 (USD Billion)
  12. Latin America Pharmacies Market, By Region, From 2021 to 2026 (USD Billion)
  13. Latin America Clinics Market, By Region, From 2021 to 2026 (USD Billion)
  14. Latin America E-commerce Market, By Region, From 2021 to 2026 (USD Billion)
  15. Brazil Gastroparesis Drugs Market, By Drug Class, From 2021 to 2026 (USD Billion)
  16. Brazil Gastroparesis Drugs Market, By Disease Type, From 2021 to 2026 (USD Billion)
  17. Brazil Gastroparesis Drugs Market, By End User, From 2021 to 2026 (USD Billion)
  18. Argentina Gastroparesis Drugs Market, By Drug Class, From 2021 to 2026 (USD Billion)
  19. Argentina Gastroparesis Drugs Market, By Disease Type, From 2021 to 2026 (USD Billion)
  20. Argentina Gastroparesis Drugs Market, By End User, From 2021 to 2026 (USD Billion)
  21. Mexico Gastroparesis Drugs Market, By Drug Class, From 2021 to 2026 (USD Billion)
  22. Mexico Gastroparesis Drugs Market, By Disease Type, From 2021 to 2026 (USD Billion)
  23. Mexico Gastroparesis Drugs Market, By End User, From 2021 to 2026 (USD Billion)
  24. Rest of Latin America Gastroparesis Drugs Market, By Drug Class, From 2021 to 2026 (USD Billion)
  25. Rest of Latin America Gastroparesis Drugs Market, By Disease Type, From 2021 to 2026 (USD Billion)
  26. Rest of Latin America Gastroparesis Drugs Market, By End User, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 2875

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample